Company intelligence / Profile preview

MN1.com

Melbourne, Victoria, Australia

Ownership: Private
Development stage: Other

Overview

MN1 Therapeutics is a biotechnology company focused on developing first-in-class small molecule therapies for Acute Myeloid Leukemia (AML) driven by the MN1 oncogene. The company targets the MN1 protein, a transcriptional co-activator that is frequently overexpressed in aggressive leukemias, leading to poor clinical outcomes and resistance to standard treatments. By disrupting the interaction between MN1 and its transcriptional partners, MN1 Therapeutics aims to reverse the leukemic phenotype and provide a precision medicine approach for high-risk patients. The company's technology is based on foundational research from the Peter MacCallum Cancer Centre and is supported by leading life science investors.

Therapeutic areas: Hematology
Modalities: Small molecule
Industry: Biotech

Partnerships

Peter MacCallum Cancer Centre

Beyond the preview

Go deeper on MN1.com.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MN1.com.

Explore the full profile